AACR 2025 Recap: Immunotherapy Shifts, ctDNA Surveillance, and Breakthroughs in HER2 and AML

In this post-conference episode, Mike breaks down five major stories from AACR 2025:

• KEYNOTE-689 trial changes the standard of care in head and neck cancer
• Zongertinib delivers HER2-targeted efficacy with fewer side effects in lung cancer
• CAR NK cells show durable remission in AML
• ctDNA testing in CRC detects recurrence 6+ months before imaging
• Werner helicase inhibitor shows first-in-class potential in MSI tumors

Listen in for a concise roundup of the data and why it matters.